Catalyst Pharmaceuticals is studying amifampridine phosphate in a number of neurological orphan indications, such as LEMS, CMS, and MuSK-MG.  Other pipeline programs include CPP-115, which is under investigation in several neurological conditions, such as epilepsy, Tourette’s syndrome, and infantile spasms.